辅酶Q10的影响在早期帕金森病:放缓的证据功能的下降。

文章的细节

引用

复制到剪贴板

Shults CW,奥克斯D, Kieburtz K,比尔曼氏金融,哈斯R,垂直年代,灯芯草雀杰,纳特J, Shoulson我,卡特J, Kompoliti K,波尔马特JS,帝国,斯特恩,瓦特RL, Kurlan R, Molho E,哈里森米、卢米

辅酶Q10的影响在早期帕金森病:放缓的证据功能的下降。

拱神经。2002年10月,59 (10):1541 - 50。

PubMed ID

12374491 (在PubMed

]

文摘

背景:帕金森病(PD)是一种退行性神经系统疾病的治疗可以减缓病情发展。目的:确定一个范围的辅酶Q10的剂量是安全,耐受性良好,可以减缓PD功能下降。与这些相应平行的组织设计:多中心,随机,安慰剂对照,双盲dosage-ranging试验。设置:学术运动障碍诊所。病人:不需要治疗的八十例早期PD的残疾。干预措施:随机分配在剂量安慰剂或辅酶Q10, 300年600,或1200毫克/天。主要结果测量:受试者接受评估的统一帕金森病评定量表(UPDRS)筛查、基线,和1 - 4 -,8 - 12 - 16个月的访问。他们随访16个月,或者直到残疾需要用左旋多巴治疗了。主反应变量的变化是总分的UPDRS从基线到最后一次访问。结果:调整意味着总UPDRS变化为安慰剂组+ 11.99,+ 8.81 300 - mg / d组,+ 10.82 600 - mg / d组,和+ 6.69 1200 - mg / d组。 The P value for the primary analysis, a test for a linear trend between the dosage and the mean change in the total UPDRS score, was.09, which met our prespecified criteria for a positive trend for the trial. A prespecified, secondary analysis was the comparison of each treatment group with the placebo group, and the difference between the 1200-mg/d and placebo groups was significant (P =.04). CONCLUSIONS: Coenzyme Q10 was safe and well tolerated at dosages of up to 1200 mg/d. Less disability developed in subjects assigned to coenzyme Q10 than in those assigned to placebo, and the benefit was greatest in subjects receiving the highest dosage. Coenzyme Q10 appears to slow the progressive deterioration of function in PD, but these results need to be confirmed in a larger study.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Ubidecarenone